ストックスクリーナーアプリを入手
4.64
2.88%
0.13
アフターアワーズ：
4.64
前日終値:
$4.51
開ける：
$4.38
24時間の取引高:
343.54K
Relative Volume:
1.64
時価総額：
$271.54M
収益：
$2.76M
当期純損益:
$-49.12M
株価収益率:
-3.0933
EPS:
-1.5
ネットキャッシュフロー:
$-46.21M
1週間 パフォーマンス:
+5.94%
1か月 パフォーマンス:
+16.58%
6か月 パフォーマンス:
+90.16%
1年 パフォーマンス:
+4.74%
1日の値動き範囲:
$4.38
$4.64
1週間の範囲:
$4.09
$4.72
52週間の値動き範囲:
$2.20
$5.424
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
名前
Orchestra Biomed Holdings Inc
セクター
電話
646-343-9298
住所
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
4.64 | 263.93M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | 開始されました | TD Cowen | Buy |
| 2025-08-20 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-03-20 | 開始されました | BTIG Research | Buy |
| 2025-01-02 | 開始されました | Barclays | Overweight |
| 2024-08-22 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-25 | 開始されました | B. Riley Securities | Buy |
| 2024-01-19 | 開始されました | Jefferies | Buy |
| 2023-02-24 | 開始されました | Piper Sandler | Overweight |
| 2023-02-07 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Orchestra Biomed Holdings Inc (OBIO) 最新ニュース
Analysts’ Top Healthcare Picks: Orchestra BioMed Holdings (OBIO), Cardinal Health (CAH) - The Globe and Mail
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Orchestra BioMed reports 2025 results, advances pivotal clinical trials - MSN
Aug Highlights: Will Orchestra BioMed Holdings Inc benefit from geopolitical trends2026 Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
HC Wainwright Has Optimistic Outlook of OBIO Q1 Earnings - MarketBeat
Orchestra BioMed Reports 2025 Results, Advances Pivotal Clinical Trials - MyChesCo
Orchestra BioMed (NASDAQ:OBIO) Insider Purchases 10,000 Shares - MarketBeat
Orchestra BioMed (NASDAQ:OBIO) Raised to Hold at Wall Street Zen - MarketBeat
Orchestra BioMed (OBIO) First Profitable Quarter Tests Bearish Unprofitability Narrative - simplywall.st
Orchestra BioMed Holdings (OBIO) Receives a Buy from Chardan Capital - The Globe and Mail
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm
Orchestra BioMed Holdings, Inc. (OBIO) surpasses Q4 earnings and revenue estimates - MSN
Orchestra BioMed (NASDAQ:OBIO) Receives "Buy" Rating from Chardan Capital - MarketBeat
Chardan reiterates Orchestra BioMed stock rating on trial focus By Investing.com - Investing.com Canada
Chardan reiterates Orchestra BioMed stock rating on trial focus - Investing.com
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Orchestra BioMed Holdings, Inc. (OBIO) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
OBIO: Revenue up 1,539% to $33.5M; strong cash, pivotal trials advancing, more proceeds expected - TradingView
Orchestra BioMed Reports $106.5 Million Cash Position and Major Financial Milestones for 2025 - Quiver Quantitative
Orchestra BioMed Holdings 10-K Summary — Revenue: $— | EPS: $— - TradingView
Orchestra BioMed Secures $30 Million Terumo Deal for Coronary Device Rights - MSN
Aug Analyst Calls: Will Orchestra BioMed Holdings Inc benefit from AI trendsTrade Risk Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Why Orchestra BioMed Holdings Inc. stock could outperform in 2026Portfolio Update Report & Risk Managed Trade Strategies - Naître et grandir
Insider Sell: How resilient is Orchestra BioMed Holdings Inc. stock in market downturns2025 Key Highlights & Verified Short-Term Trading Plans - Naître et grandir
Market Leaders: Does Orchestra BioMed Holdings Inc outperform in volatile markets2025 Buyback Activity & Stepwise Trade Execution Plans - baoquankhu1.vn
Orchestra BioMed to present hypertension therapy data at medical meetings By Investing.com - Investing.com Canada
Orchestra BioMed announces presentations highlighting Avim therapy potential impact on hypertensive heart disease and heart failure at THT and CRT - marketscreener.com
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT - The Manila Times
Orchestra BioMed to present hypertension therapy data at medical meetings - Investing.com
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
OBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
RTW INVESTMENTS, LP Increases Stake in Orchestra BioMed Holdings Inc - GuruFocus
Medtronic (OBIO) affiliates hold 17.8% of Orchestra BioMed in amended 13G/A - Stock Titan
Earnings Beat: How much upside does Orchestra BioMed Holdings Inc have2025 Fundamental Recap & Accurate Technical Buy Alerts - baoquankhu1.vn
Orchestra BioMed to Present at Two Healthcare Conferences - MyChesCo
Gains Report: Is Tuya Inc Depositary Receipt a play on infrastructure spending - baoquankhu1.vn
OBIOOrchestra BioMed Holdings Inc Latest Stock News & Market Updates - Stock Titan
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Orchestra BioMed Holdings (OBIO) and Teladoc (TDOC) - The Globe and Mail
Orchestra BioMed grants inducement stock options to nine new employees - MSN
Will Orchestra BioMed Holdings Inc. benefit from geopolitical trendsJuly 2025 Decliners & Real-Time Volume Analysis Alerts - mfd.ru
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewswire
Orchestra BioMed (NASDAQ:OBIO) Trading 4.2% HigherHere's What Happened - MarketBeat
Orchestra BioMed Grants Inducement Stock Options to Nine New Employees - MyChesCo
Earnings Recap: Will MITTPRA stock hit new highs in YEARQuarterly Earnings Report & Expert Approved Trade Ideas - baoquankhu1.vn
Orchestra BioMed announces inducement grants - Medical Buyer
What is Orchestra BioMed Holdings Inc. s P E ratio telling usJuly 2025 Drop Watch & Low Risk Profit Maximizing Plans - mfd.ru
Orchestra BioMed Adopts 2026 Performance-Driven Executive Compensation Plan - TipRanks
Orchestra BioMed Grants Stock Options to New Employees as Part of 2025 Inducement Plan - Quiver Quantitative
Does Orchestra BioMed Holdings Inc. outperform in volatile markets2025 Price Targets & Growth Focused Investment Plans - mfd.ru
Orchestra Biomed Holdings Inc (OBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.20%
0.06%
大文字化:
|
ボリューム (24 時間):